Exciting New Developments in Cancer Diagnostics
Biodesix, Inc. (NASDAQ: BDSX), a front-runner in diagnostic solutions, is preparing to share groundbreaking data at two major upcoming scientific meetings. These presentations will focus on the company's latest advancements in lung cancer diagnostics and breast cancer treatment resistance.
Presentation Highlights at Upcoming Conferences
At the North American Conference on Lung Cancer (NACLC), taking place in Chicago, Biodesix will present new findings regarding its Nodify Lung tests. These findings illustrate the crucial role of prompt lung nodule risk classification in facilitating the early diagnosis of lung cancer. Attendees can look forward to significant contributions from the following research projects:
- Refining Post-test Probability of Lung Cancer Using Post-Market Data from a Blood-based Biomarker Test in Pulmonary Nodule Patients.
Presented by Michael N. Kammer, PhD (Biodesix Head of Radiomics). - Modeling the Impact of an Autoantibody Blood Test for Lung Cancer on Time to Diagnosis in Pulmonary Nodule Assessment: A Multi-Cohort Analysis.
Presented by Kathryn Long, MD.
New ESR1 Assay for Breast Cancer Monitoring
Additionally, Biodesix will showcase its cutting-edge research on an ultra-sensitive ESR1 assay during the San Antonio Breast Cancer Symposium. This innovative test allows for both the initial detection and ongoing monitoring of hormone receptor-positive breast cancers. This test is currently available to biopharmaceutical partners as part of Biodesix's Development Services, which bolster the ability to expedite the development of diagnostic tests and therapies.
Key Details of the Breast Cancer Symposium Presentation
- Poster Session 4, PS4-02-29: Development of an ultra-sensitive droplet digital PCR test for monitoring ESR1 variants in liquid biopsies.
Presented by Leisa Jackson, a Biodesix staff scientist.
Honors from Recent ISPOR Meeting
In November, at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe meeting, Biodesix received prestigious accolades for its work on healthcare costs associated with pulmonary nodules. The company was awarded a Best General Poster Research Presentation and a Top 5% Research Certificate, reflecting its significant contributions to the field.
Research Highlights from ISPOR Meeting
- PT5: Pulmonary Nodule (PN)-Related and Lung Cancer-Related Workup Costs Within the Two-Year Period After Diagnosis of a PN in the United States.
Presented by Kimberly Le, MBA, MS, PharmD.
About Biodesix
Biodesix is dedicated to improving clinical care and patient outcomes through innovative diagnostic solutions. Its notable tests, such as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, empower clinical decisions to tailor personalized care for lung disease patients. Biodesix's Development Services aim to assist biopharmaceutical and life sciences organizations, fostering the advancement of diagnostic tests, tools, and therapeutic interventions.
Contact Information for Biodesix
Media Contacts:
Natalie St. Denis, Director of Corporate Communications
natalie.stdenis@biodesix.com
(720) 925-9285
Investor Contacts:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843
Frequently Asked Questions
What presentations will Biodesix be making at the NACLC?
Biodesix will present findings related to its Nodify Lung tests, showcasing their role in early lung cancer diagnosis through risk classification.
What is the significance of the new ESR1 assay presented by Biodesix?
This assay is designed for monitoring hormone receptor-positive breast cancer treatments, providing vital insights into treatment resistance.
What recognitions did Biodesix receive at the ISPOR meeting?
Biodesix was awarded for its research on healthcare costs associated with pulmonary nodules, receiving a Best General Poster Research Presentation and a Top 5% Research Certificate.
How does Biodesix support personalized care?
Biodesix's diagnostic tests help clinicians make informed decisions, ensuring tailored and effective treatment plans for patients with lung diseases.
Where can I find more information about Biodesix?
Additional information can be found on the company's website, biodesix.com.